FERTILITY CAPSULE I (FSH, LH, PROLACTIN)

Fertility Capsule I is a combined hormone blood-test panel that measures Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH) and prolactin. These hormones are produced mainly by the pituitary gland and play important roles in menstrual-cycle regulation, ovarian function, ovulation and reproductive health.

The reproductive system depends on coordinated signalling between the hypothalamus, pituitary gland and ovaries. FSH supports the growth and development of ovarian follicles. LH contributes to the final maturation of a follicle and helps trigger ovulation. Prolactin is best known for supporting breast-milk production, but an abnormally elevated level may interfere with reproductive-hormone signalling and menstrual regularity.

This panel may provide useful information during the evaluation of difficulty conceiving, irregular periods, absent periods or suspected ovulation problems. Results must be interpreted according to age, symptoms, menstrual-cycle phase, medicine use, pregnancy status and other investigations. The panel does not independently establish the complete cause of infertility.

Benefits of the Test

• Measures three important pituitary hormones associated with reproductive health.
• Supports assessment of follicle development and ovarian stimulation through FSH.
• Provides information about ovulation-related hormonal activity through LH.
• Helps identify elevated prolactin that may disrupt periods or ovulation.
• Supports evaluation of irregular or absent menstrual periods.
• May contribute to the assessment of difficulty becoming pregnant.
• Can help doctors investigate possible ovarian, pituitary or hypothalamic dysfunction.
• Provides baseline values before selected fertility treatments.

Why Doctors Recommend This Test

A doctor may recommend Fertility Capsule I when a woman has difficulty conceiving, irregular menstrual cycles, absent periods or symptoms suggesting abnormal ovulation. It may also be requested before or during fertility treatment to evaluate reproductive-hormone patterns.

FSH stimulates follicles in the ovaries to grow during the first part of the menstrual cycle. Its level changes throughout the cycle. An elevated early-cycle FSH result may occur when the ovaries respond less effectively to pituitary stimulation. Low or inappropriately normal FSH may be associated with certain hypothalamic or pituitary conditions. An isolated FSH result cannot determine ovarian reserve or fertility potential.

LH works with FSH to regulate ovarian function. A rapid increase in LH normally occurs before ovulation. Abnormal LH patterns may occur with polycystic ovary syndrome, reduced ovarian function or disorders affecting the hypothalamus and pituitary gland. A single blood measurement does not always show whether ovulation has occurred because LH changes considerably across the menstrual cycle.

Prolactin is produced by the pituitary gland. Persistently elevated prolactin may interfere with the release of reproductive hormones, leading to irregular periods, absent periods, reduced ovulation or infertility. It may also cause unexpected breast-milk production. High prolactin can be associated with pregnancy, breastfeeding, hypothyroidism, certain medicines, kidney disease or a pituitary condition.

Because stress, recent exercise, sleep and breast stimulation may temporarily increase prolactin, a mildly elevated result may need to be repeated under controlled conditions. The doctor may request additional investigations based on the degree of elevation and the patient's symptoms.

Preparation Before Test

Fasting is generally not required unless the doctor or laboratory provides specific instructions. The collection date and time may be important because FSH and LH vary across the menstrual cycle. These hormones are often measured during the early follicular phase, commonly around cycle day 2 or 3, when evaluating baseline reproductive function. Follow the exact timing recommended by the treating doctor.

Prolactin levels vary during the day and are influenced by sleep. The laboratory may recommend collecting the sample in the morning after the patient has been awake for a specified period. Rest quietly before sample collection if instructed, as anxiety and physical exertion may temporarily increase prolactin.

Avoid strenuous exercise and breast or nipple stimulation before the test when advised. Inform the healthcare professional if you are pregnant, breastfeeding or recently delivered a baby because these conditions naturally affect prolactin.

Provide the date of the last menstrual period, usual cycle length and information about irregular bleeding. Inform the doctor about fertility medicines, hormonal contraceptives, antipsychotic medicines, antidepressants, anti-nausea medicines, thyroid treatment and all other medicines or supplements. Do not stop prescribed treatment unless instructed by the doctor.

A healthcare professional will collect a small blood sample from a vein, usually in the arm. The procedure generally takes only a few minutes and requires no recovery period.

Normal Reporting Time

The Fertility Capsule I report is commonly available on the same day or within 24 hours after the laboratory receives a suitable blood sample. Reporting time may vary according to the collection time, laboratory workflow, analytical schedule, quality-control checks and result verification requirements.

Who Should Take This Test?

This panel may be appropriate for women experiencing difficulty becoming pregnant, irregular menstrual cycles, absent periods or suspected ovulation problems. It may also be considered when symptoms suggest elevated prolactin, such as unexpected breast discharge, headaches or menstrual changes.

Doctors may request the test when investigating possible polycystic ovary syndrome, reduced ovarian function, early menopause or hypothalamic and pituitary disorders. Depending on the clinical purpose, these hormones may also be assessed in males with infertility, reduced sexual function or suspected pituitary abnormalities, although interpretation and reference ranges differ.

Fertility Capsule I is not a complete fertility assessment. Other tests may include AMH, estradiol, progesterone, TSH, pelvic ultrasound, antral follicle count, tubal-patency testing and semen analysis of the male partner.

Detailed Information

FSH is released by the anterior pituitary gland. In women, it promotes the growth of ovarian follicles and contributes to estrogen production. FSH concentrations change according to menstrual-cycle phase, age and ovarian feedback. The result must therefore be compared with the appropriate cycle-phase reference interval.

LH is also produced by the anterior pituitary gland. During the middle of the menstrual cycle, an LH surge helps trigger the release of an egg from the dominant follicle. After ovulation, LH supports the corpus luteum, which produces hormones necessary for the second half of the menstrual cycle.

The relationship between LH and FSH may provide additional clinical information, but a particular LH-to-FSH ratio should not be used alone to diagnose polycystic ovary syndrome. Diagnosis requires consideration of menstrual history, clinical signs, biochemical findings and, when appropriate, ovarian ultrasound.

Prolactin secretion is regulated partly by dopamine. Its concentration normally increases during pregnancy and breastfeeding. Outside these conditions, persistently elevated prolactin may suppress reproductive-hormone signalling. If an elevated result is found, the doctor may repeat the test and assess TSH, kidney function, medicine use or pituitary function.

Macroprolactin is a larger form of prolactin that may be detected by some laboratory assays but may have less biological activity. In selected patients with an elevated prolactin result and limited symptoms, the doctor may request macroprolactin evaluation.

Hormone results vary according to age, sex, menstrual phase, pregnancy status, collection time, medicines and laboratory method. The reference ranges printed on the individual report should be used. Results should be reviewed by a gynaecologist, fertility specialist or another qualified healthcare professional together with clinical history and additional investigations.